EX-10.1



 Exhibit 10.1 

SUBSCRIPTION AGREEMENT 

This Subscription Agreement (this “Agreement”) is dated September 6, 2016, among Anthera Pharmaceuticals, Inc. a
Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its permitted successors and assigns, a “Purchaser” and collectively the
“Purchasers”). 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective
registration statement filed pursuant to the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, shares of Preferred Stock
and warrants to purchase shares of Common Stock (each as defined below and as more fully described in this Agreement). 
 NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: 

ARTICLE I 
 DEFINITIONS

 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
set forth in this Section 1.1: 
 “Affiliate” means any Person that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under common control with a Person (as such terms are used in and construed under Rule 405 of the Securities Act). With respect to a Purchaser, any investment fund or managed
account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 

“Certificate of Incorporation” means the Company’s Fifth Amended and Restated Certificate of
Incorporation, as amended from time to time. 
 “Closing” means the closing of the purchase and sale of the
Securities on the Initial Closing Date or the Second Closing Date, as applicable, pursuant to Section 2.1 of this Agreement. 

“Commission” means the U.S. Securities and Exchange Commission. 

“Common Stock” means the common stock of the Company, $0.001 par value per share, and any other class of
securities into which such securities may hereafter be reclassified or changed into. 
 “Common Stock
Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof, pursuant to the terms of such securities, 







 
to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Exchange Act” means
the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder. 
 “Exempt
Issuance” means: (a) the issuance of shares of Common Stock, options to purchase Common Stock and other securities convertible into or exchangeable for Common Stock pursuant to any plan or agreement, the issuance of securities under
which would be eligible to be registered on Form S-8 under the Securities Act (regardless of whether such issuance is actually registered on Form S-8), and (b) the offer and sale of up to 1,000,000 shares of Common Stock pursuant to the
Company’s existing at-the-market offering facility, with H.C. Wainwright & Co. as sales agent, as described in that certain prospectus supplement, dated April 21, 2016 (Registration No. 333-210166). 

“Subscription Notice” shall mean a notice electing to subscribe for shares of Series X-1 Preferred Stock, in
the form attached hereto as Exhibit D. 
 “Fundamental Transaction” means (a) the Company
effects any merger or consolidation of the Company with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of
arrangement) with or into another Person (other than such a transaction in which the Company is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (b) the Company
effects any sale of all or substantially all of its assets in one transaction or a series of related transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which more than 50% of
the Common Stock not held by the Company or such Person is exchanged for or converted into other securities, cash or property, or (d) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other
than as a result of a dividend, subdivision or combination) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property. 

“Indebtedness” means (a) any liabilities for borrowed money or amounts owed in excess of $250,000 (other
than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others, whether or not the same are or should be reflected in the
Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business, and (c) the present value of any lease
payments in excess of $250,000 due under leases required to be capitalized in accordance with GAAP. 
 “Initial
Closing” means the closing of the purchase and sale of Securities on the Initial Closing Date pursuant to Section 2.1 of this Agreement. 

  
 2 








 “Initial Closing Date” means the third Trading Day after the
date hereof. 
 “Investment Company Act” means the Investment Company Act of 1940, as amended. 

“Lead Investors” means Biotechnology Value Fund, L.P. and Rock Springs Capital Master Fund LP. 

“Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or
other restriction (other than, in the case of the Securities, restrictions provided in the Transaction Documents or as otherwise agreed or imposed by a Purchaser). 

“Material Adverse Effect” means any material adverse effect on (a) the enforceability of any Transaction
Document, (b) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, or (c) the Company’s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document to be performed as of the date of determination, other than any such change, effect, event or circumstance, including, without limitation, any change in the stock price or trading volume of the Common Stock, that
resulted exclusively from (i) any change in the United States or foreign economies or securities or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, (ii) any change that
generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (iii) any change arising in connection with natural disasters,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such natural disasters, hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof,
(iv) any action taken by the Purchaser, its Affiliates or its or their permitted successors and assigns with respect to the transactions contemplated by this Agreement, (v) the effect of any changes in applicable laws or accounting rules
that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, and (vi) any change resulting from compliance with the terms of this Agreement or the consummation of the transactions contemplated by this
Agreement. 
 “Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Preferred Stock” means the Series X Preferred Stock and the Series X-1 Preferred Stock. 

“Proceeding” means any action, claim, suit, investigation or proceeding whether commenced or threatened. 

“Prospectus” means the final prospectus filed for the Registration Statement, including the documents
incorporated by reference in the Registration Statement, including the documents incorporated by reference in such final prospectus. 

  
 3 








 “Prospectus Supplement” means the supplement to the Prospectus
complying with Rule 424(b) of the Securities Act that is delivered by the Company to each Purchaser prior to the execution and delivery of this Agreement, including the documents incorporated by reference therein, and that is filed with the
Commission. 
 “Registration Statement” means the effective registration statement on Form S-3 (Commission
File No. 333-210166) filed by the Company with the Commission pursuant to the Securities Act for the registration of the Securities, as such Registration Statement may be amended and supplemented from time to time (including pursuant to Rule
462(b) of the Securities Act), including all documents filed as part thereof or incorporated by reference therein, and including all information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B of the Securities Act.

 “Required Minimum” means, as of any date, the maximum aggregate number of shares of Common Stock then
issued or potentially issuable pursuant to the Transaction Documents, including all Underlying Shares, and without regard to any conversion blockers. 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Second Closing” means the closing of the purchase and sale of the Series X-1 Preferred Stock on the Second
Closing Date pursuant to Section 2.1 of this Agreement. 
 “Second Closing Date” means the third
Trading Day after the date of the Subscription Notice. 
 “Second Subscription Amount” means, as to each
Purchaser, the aggregate amount to be paid for the Securities purchased hereunder at the Second Closing as specified below such Purchaser’s name on the applicable Subscription Notice in United States dollars and in immediately available funds.

 “Securities” means the shares of the Preferred Stock and Warrants issued hereunder and the Underlying
Shares. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 “Series X Preferred Stock” means the Series X Convertible Preferred Stock of the
Company, $0.001 par value per share. 
 “Series X Preferred Stock Certificate of Designation” means the
Certificate of Designation of the Company, attached as Exhibit A to this Agreement, setting forth the rights preferences and privileges of the Series X Preferred Stock. 

  
 4 








 “Series X-1 Preferred Stock” means the Series X-1 Convertible
Preferred Stock of the Company, $0.001 par value per share. 
 “Series X-1 Preferred Stock Certificate of
Designation” means the Certificate of Designation of the Company, attached as Exhibit B to this Agreement, setting forth the rights preferences and privileges of the Series X-1 Preferred Stock. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO of the Exchange Act,
but shall be deemed to not include the location and/or reservation of borrowable shares of Common Stock. 

“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for the Securities
purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available funds. 

“Trading Day” means a day on which the Common Stock is traded on a Trading Market. 

“Trading Market” means the following markets or exchanges on which (and if) the Common Stock is listed or
quoted for trading on the date in question: the NYSE MKT; The NASDAQ Capital Market; The NASDAQ Global Market; The NASDAQ Global Select Market; or the New York Stock Exchange. 

“Transaction Documents” means this Agreement and any other documents or agreements executed and delivered to
the Purchasers in connection with the transactions contemplated hereunder, including, but not limited to, the Series X Preferred Stock Certificate of Designation, Series X-1 Preferred Stock Certificate of Designation and the Warrants. 

“Underlying Shares” means the shares of Common Stock issued and issuable upon conversion or exercise of the
Series X Preferred Stock, the Series X-1 Preferred Stock, the Warrants and any other shares of Common Stock issuable to the Purchasers in connection with or pursuant to the Transaction Documents. 

“Warrants” means, collectively, each Warrant issued at the Initial Closing and exercisable for shares of
Common Stock, in the form attached as Exhibit C to this Agreement. 
 ARTICLE II 

PURCHASE AND SALE 
 2.1
Initial Closing. At the Initial Closing, upon the terms set forth herein, the Company shall sell, and the Purchasers shall purchase, in the aggregate, severally and not jointly, (i) $17,000,000, in the aggregate, of Series X
Preferred Stock, with each Purchaser purchasing Series X Preferred Stock with an aggregate purchase price equal to such Purchaser’s Subscription Amount and (ii) a Warrant to purchase up to the number of shares of Common Stock equal to
twenty-five percent (25%) of the number of shares of Common Stock issuable 

  
 5 








 
upon conversion of the Series X Preferred Stock purchased by such Purchaser. The aggregate number of shares of Series X Preferred Stock sold hereunder shall be 17,000. Each Purchaser shall
deliver to the Company via wire transfer or certified check immediately available funds equal to its Subscription Amount and the Company shall deliver to each Purchaser its respective shares of Series X Preferred Stock and Warrants as determined
pursuant to Section 2.3(a) of this Agreement and the other items set forth in Section 2.3 of this Agreement deliverable at the Closing on the Initial Closing Date. The Closing shall occur at 10:00 a.m., Pacific Time, at the
offices of Goodwin Procter LLP, Three Embarcadero Center, 24th Floor, San Francisco, California 94111, or such other time and location as the parties shall mutually agree. 

2.2 Second Closing. 

(a) From the date hereof, through the date that is 20 Trading Days following the Company’s first filing of a Current Report on Form 8-K
(the “Solution 8-K”) disclosing top-line clinical efficacy and safety data from the Company’s ongoing “SOLUTION” clinical study (Phase 3 study evaluating the efficacy and safety of Liprotamase in subjects with cystic
fibrosis-related exocrine pancreatic insufficiency) (the “Subscription Period”), the Purchasers shall have the right, but not the obligation, in their sole discretion, to subscribe for and purchase up to an aggregate of 28,330
shares of Series X-1 Preferred Stock in the Second Closing (the “Second Closing Shares”), severally and not jointly, corresponding with a potential investment of $28,330,000, with each Purchaser having the right to purchase up to
the following number of shares of Series X-1 Preferred Stock (i) the entities affiliated with Biotechnology Value Fund, L.P. shall be entitled to purchase up to $25,000,000 in shares of Series X-1 Preferred Stock and (ii) the entities
affiliated with Rock Springs Capital Master Fund LP shall be entitled to purchase up to $3,330,000 in shares of Series X-1 Preferred Stock. 

  
 6 








 (b) If one or more of the Purchasers elects through a Subscription Notice (which shall be
delivered to the Company prior to 5:30 p.m. (Pacific Time) on the last day of the Subscription Period) to purchase part or all of the Second Closing Shares, then the Company shall sell, and the Purchasers shall purchase, in the aggregate, severally
and not jointly, that number of Second Closing Shares as indicated in the Subscription Notice at a price of $1,000 per share of Series X-1 Preferred Stock. Each Purchaser participating in the Second Closing shall deliver to the Company via wire
transfer or certified check then immediately available funds equal to its Second Subscription Amount, and the Company shall deliver to each Purchaser its respective shares of Series X-1 Preferred Stock. The Second Closing shall occur at 10:00 a.m.,
Pacific Time on the Second Closing Date, at the offices of Goodwin Procter LLP, Three Embarcadero Center, 24th Floor, San Francisco, California 94111, or such other time and location as the parties shall mutually agree. 

2.3 Deliveries; Closing Conditions. 

(a) Prior to the Initial Closing, the Company shall have adopted and filed with the Secretary of State of the State of Delaware the Series X
Preferred Stock Certificate of Designation, and the Series X Preferred Stock Certificate of Designation shall be in full force and effect. 

(b) Prior to the Second Closing, the Company shall have adopted and filed with the Secretary of State of the State of Delaware the Series X-1
Preferred Stock Certificate of Designation, and the Series X-1 Preferred Stock Certificate of Designation shall, of such time, be in full force and effect. 

(c) At the Initial Closing, the Company shall (i) deliver or cause to be delivered to each Purchaser evidence that the number of shares
(including any fractions thereof) of Series X Preferred Stock equal to such Purchaser’s Subscription Amount, divided by $1,000 (representing the per-share price) have been recorded in book entry form in the name of such Purchaser as beneficial
owner on the records of the Company’s transfer agent, American Stock Transfer & Trust Company, LLC and (ii) issue to each Purchaser a Warrant; 

(d) At the Second Closing, the Company shall deliver or cause to be delivered to each Purchaser evidence that the number of shares (including
any fractions thereof) of Series X-1 Preferred Stock equal to such Purchaser’s Second Subscription Amount divided by $1,000 (representing the per-share price) have been recorded in book entry form the name of such Purchaser as beneficial owner
on the records of the Company’s transfer agent, American Stock Transfer & Trust Company, LLC; 
 (e) At each Closing, each
Purchaser shall deliver or cause to be delivered to the Company such Purchaser’s Subscription Amount or Second Subscription Amount, as applicable, by wire transfer to the account as specified in writing by the Company; and 

  
 7 








 (f) The respective obligations of the Company, on the one hand, and the Purchasers, on the other
hand, hereunder in connection with each Closing are subject to the following conditions being met: 
 (i) the accuracy in all
material respects on the Initial Closing Date of the representations and warranties contained herein (unless made as of a specified date therein) of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to
the obligations of the Company); 
 (ii) all obligations, covenants and agreements of the Company (with respect to the
obligations of the Purchasers) and the Purchasers (with respect to the obligations of the Company) required to be performed at or prior to the applicable Closing shall have been performed in all material respects; 

(iii) the delivery by the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to the
obligations of the Company) of the items set forth in Section 2.3 of this Agreement; 
 (iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof; and 
 (v) from the date hereof to the
applicable Closing, trading in the Common Stock shall not have been suspended on the Company’s principal U.S. Trading Market and, at any time prior to the applicable Closing, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, on any U.S. Trading Market. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES 

3.1 Representations and Warranties of the Company. Except as set forth in the SEC Reports, which shall qualify any
representation or warranty otherwise made herein to the extent of such disclosure, the Company hereby makes the following representations and warranties set forth below to each Purchaser as of the date hereof and as of the applicable Closing: 

(a) Subsidiaries. Each of the direct and indirect subsidiaries (each, a “Subsidiary”) of the Company are set
forth on Exhibit 21.1 to the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Except as disclosed in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock
or other equity interests of each Subsidiary free and clear of any Liens, except for such Liens as would not reasonably be expected to result in a Material Adverse Effect, and all the issued and outstanding shares of capital stock of each Subsidiary
are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities of the Company. 

(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own and use its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in violation or 

  
 8 








 
default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly
qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to
be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such power and authority or qualification except where the revocation, limitation or curtailment could not have or reasonably be expected to result in a Material Adverse Effect. 

(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents to which it is a party by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of the Company and no further corporate consent or action is required to be obtained by the Company, its
Board of Directors or its shareholders in connection therewith other than in connection with the Required Approvals. Each Transaction Document has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the legally valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (d)
No Conflicts. The execution, delivery and performance of the Transaction Documents to which it is a party by the Company, the issuance and sale of the Securities and the consummation by the Company of the other transactions contemplated
hereby and thereby do not and will not (i) after giving effect to the Required Approvals, conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) after giving effect to the Required Approvals, conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of
any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or
(iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary
is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected, except in the case of each of clauses (ii) and (iii) only, such
as would not have or reasonably be expected to result in a Material Adverse Effect. 

  
 9 








 (e) Filings, Consents and Approvals. Except as disclosed in the SEC Reports and except
where the failure to obtain any such consent, waiver, authorization or order, give any such notice or make any such filing or registration would not reasonably be expected to result in a Material Adverse Effect, the Company is not required to obtain
any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person or other entity of any kind, including, without
limitation, any Trading Market in connection with the execution, delivery and performance by the Company of the Transaction Documents, except for any filings required to be made under applicable federal and state securities laws and the listing
applications with respect to the listing of the Securities required pursuant to Section 4.6 (collectively, the “Required Approvals”). 

(f) Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Securities are being issued pursuant to the Registration Statement and the issuance of the Securities will
be registered by the Company pursuant to the Securities Act. The Company has prepared and filed with the Commission in accordance with the provisions of the Securities Act the Registration Statement. The Registration Statement is effective pursuant
to the Securities Act and available for the issuance of the Securities thereunder and the Company has not received any written notice that the Commission has issued or intends to issue a stop-order or other order with respect to the Registration
Statement or the Prospectus or that the Commission otherwise has (i) suspended or withdrawn the effectiveness of the Registration Statement or (ii) issued any order preventing or suspending the use of the Prospectus, in either case, either
temporarily or permanently or intends or has threatened in writing to do so. The “Plan of Distribution” section of the Registration Statement permits the issuance of the Securities hereunder. Upon receipt of the Securities, the Purchasers
will have good and marketable title to such Securities and, upon issuance in compliance with the terms of the Transaction Documents, the Underlying Shares will be immediately freely tradable on each Trading Market. At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at each deemed effective date thereof pursuant to Rule 430B(f)(2) of the Securities Act, the Registration Statement and any amendments thereto complied and
will comply in all material respects with the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and as of the Closing, complied and will comply in all material respects
with the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. The Company meets all of the requirements for the use of a registration statement on Form S-3 (“Form S-3”) pursuant to the Securities Act for the offering and sale of the Securities contemplated by
this Agreement, and the Commission has not notified the Company of any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(1) of the Securities Act. The Registration Statement, as of its effective date, meets
the requirements set forth in Rule 415(a)(1)(x) pursuant to the Securities Act. At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule
164(h)(2) of the Securities Act) relating to any of the Securities, the Company was not and is not an Ineligible Issuer (as defined in Rule 405 of the Securities Act). 

  
 10 








 (g) Capitalization. Except as disclosed in the SEC Reports, the Company has not issued any
capital stock since its most recently filed periodic report pursuant to the Exchange Act, other than pursuant to the exercise of stock options pursuant to the Company’s equity incentive plans, the issuance of shares of Common Stock to
employees, directors and consultants pursuant to the Company’s equity incentive plans and stock purchase plans, and pursuant to the conversion or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed
periodic report pursuant to the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation or any similar right to participate in the transactions contemplated by the Transaction Documents. Except for various
outstanding series of convertible debt, options and warrants described in the SEC Reports, there are no outstanding series of convertible stock, options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other
securities to any Person other than the Purchasers, and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such Securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and non-assessable, and none of such outstanding shares were issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Other than the Required
Approvals, no further approval or authorization after the date hereof of any shareholder, the Board of Directors of the Company or others is required for the issuance and sale of the Securities. Except as disclosed in the SEC Reports or as
contemplated by this Agreement or as otherwise agreed by a Purchaser, there are no shareholder agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the
knowledge of the Company, between or among any of the Company’s shareholders. 
 (h) SEC Reports; Financial Statements. The
Company has complied in all material respects with requirements to file all reports, schedules, forms, statements and other documents required to be filed by it pursuant to the Securities Act and the Exchange Act, including, without limitation,
pursuant to Section 13(a) or 15(d) thereof, for the two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits
thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of
such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, the rules and regulations of the Commission promulgated thereunder and other federal, state and local laws, rules and regulations applicable to it, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact 

  
 11 








 
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the
Company included in the SEC Reports, together with the related notes and schedules thereto, comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission and all other applicable rules and
regulations with respect thereto as in effect at the time of filing. Such financial statements, together with the related notes and schedules, have been prepared in accordance with United States generally accepted accounting principles
(“GAAP”) applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (i) Material Changes; Undisclosed Events,
Liabilities or Developments. Except as disclosed in the SEC Reports or as otherwise contemplated by this Agreement, since the date of the latest audited financial statements included within the SEC Reports, (i) there has been no event,
occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued
expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or required to be disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, and (iv) the Company has not issued any equity securities to any officer, director or Affiliate except pursuant to existing Company equity incentive and incentive
compensation plans. Except for the issuance of the Securities contemplated by this Agreement, or as set forth in the SEC Reports, or as otherwise disclosed to the Purchasers, no event, liability or development has occurred or exists with respect to
the Company or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made that has not
been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made. 
 (j) Litigation.
Except as disclosed in the SEC Reports, there is no Proceeding pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, legal validity or enforceability of
any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable decision, reasonably be expected to result in a Material Adverse Effect. Except as disclosed in the SEC Reports, neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. Except as disclosed in the SEC
Reports, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not
issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary pursuant to the Exchange Act or the Securities Act. 

  
 12 








 (k) Labor Relations. No material labor dispute exists or, to the knowledge of the Company,
is imminent with respect to any of the employees of the Company which would reasonably be expected to result in a Material Adverse Effect. The Company and its Subsidiaries believe that their relationships with their employees are good. No executive
officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other
contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its
Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (l) Compliance. Except as
disclosed in the SEC Reports, neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the
Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is
a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) is or has been in violation of
any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except as disclosed herein and except in
each case as would not reasonably be expected to have a Material Adverse Effect. 
 (m) Regulatory Permits. Except as disclosed in
the SEC Reports, (i) the Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as
described in the SEC Reports, except where the failure to possess such permits would not have or reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and (ii) neither the Company nor any
Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit. 
 (n) Title to
Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them that is material to the business of the Company and the Subsidiaries and good and marketable title in all personal property
owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens which do not materially affect the value of such property and do not materially interfere with the use
made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties or for taxes that are being contested
in good faith and by appropriate proceedings, and except for Liens which would not reasonably be expected to result in a Material Adverse Effect. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance. 

  
 13 








 (o) Patents and Trademarks. The Company and the Subsidiaries have, or have rights to use,
all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other similar intellectual property rights currently owned by or licensed to them in connection
with the business currently operated by them that are necessary for use in the conduct of their respective businesses as described in the SEC Reports, except where the failure to so have would not reasonably be expected to have a Material Adverse
Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor any Subsidiary has received any written notice that any of the Intellectual Property Rights used by the Company or any Subsidiary violates or
infringes upon the rights of any Person, except for such as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property Rights of the Company or any Subsidiaries. 
 (p) Insurance. The
Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage. To the Company’s knowledge, such insurance contracts are accurate and complete. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost, except for such renewals or failures
to obtain similar coverage from similar insurers as would not reasonably be expected to have a Material Adverse Effect or as affect the industry generally. 

(q) Transactions With Affiliates and Employees. None of the officers or directors of the Company and, to the knowledge of the Company,
none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors) that is required to be disclosed and is not disclosed in the SEC Reports,
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, other than for (i) payment of salary, consulting fees or financial
advisory fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including restricted stock programs and stock option agreements under any stock option plan of the
Company. 
 (r) Sarbanes-Oxley. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002, as
amended, which are applicable to it as of the date hereof. 

  
 14 








 (s) Certain Fees. Other than as disclosed in the Prospectus Supplement, no brokerage or
finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. 
 (t) Investment Company. The Company is not, and immediately after receipt of payment for the Securities will not be, an
“investment company” within the meaning of the Investment Company Act. 
 (u) Registration Rights. No Person has any right
to cause the Company to effect the registration pursuant to the Securities Act of any securities of the Company, which rights will interfere with the transactions contemplated hereunder. 

(v) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the
Commission is currently contemplating terminating such registration. Except as disclosed in the SEC Reports, the Company has not, in the twelve (12) months preceding the date hereof, received notice from any Trading Market on which the Common
Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market that would result in immediate delisting. 

(w) Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in order to
render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement), or other similar anti-takeover provision pursuant to the Certificate of Incorporation (or similar charter
documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights pursuant to the Transaction Documents,
including without limitation, as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. 

(x) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2 of this Agreement, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company in a manner that would require shareholder approval pursuant to the rules of any Trading Market on which any of the
securities of the Company are listed or designated. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of any Trading Market. 

(y) Indebtedness. The SEC Reports set forth as of the dates thereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness disclosed to the Purchasers except for any such default that would not have or
reasonably be expected to result in a Material Adverse Effect. 

  
 15 








 (z) Tax Status. Except for matters that would not, individually or in the aggregate, have
or reasonably be expected to result in a Material Adverse Effect and except as disclosed in the SEC Reports, the Company and each Subsidiary have filed (or requested valid extensions thereof) all necessary federal, state and foreign income and
franchise tax returns (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and have paid or accrued all taxes shown
as due thereon, and the Company has no knowledge of a tax deficiency which has been asserted or threatened against the Company or any Subsidiary. 

(aa) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person while acting on
behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

(bb) Accountants. BDO USA, LLP (i) to the knowledge of the Company, is an independent public accountant as required by the
Exchange Act and is an independent registered public accounting firm within the meaning of the Sarbanes-Oxley Act of 2002, as amended, as required by the rules of the Public Company Accounting Oversight Board and (ii) expressed its opinion with
respect to the audited financial statements as of December 31, 2014 and 2015 and for fiscal years 2013, 2014 and 2015 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. 

(cc) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the
Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement
and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 

(dd) Acknowledgement Regarding Purchasers’ Trading Activity. Anything in this Agreement or elsewhere herein to the contrary
notwithstanding (except for Section 3.2(d) of this Agreement, which shall control), it is understood and acknowledged by the Company (i) that none of the Purchasers have been asked to agree, nor has any Purchaser agreed, to desist
from 

  
 16 








 
purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified
term, (ii) that past or future open market or other transactions by any Purchaser, including Short Sales, and specifically including, without limitation, Short Sales or “derivative” transactions, before or after the closing of this or
future transactions, may negatively impact the market price of the Company’s publicly-traded securities, (iii) that any Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a party, directly
or indirectly, presently may have a “short” position in the Common Stock, and (iv) that each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative”
transaction. The Company further understands and acknowledges that (A) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, and (B) such hedging activities (if any)
could reduce the value of the existing shareholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities, to the extent
not prohibited by this Agreement, do not constitute a breach of any of the Transaction Documents. 
 (ee) Regulation M
Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any
compensation for soliciting another to purchase any other securities of the Company. 
 (ff) Office of Foreign Assets Control.
Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or any person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Treasury Department. 
 (gg) Money Laundering. The operations of the Company and its
Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes
and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened. 

(hh) Disclosure Controls and Procedures. Except as disclosed in the SEC Reports, the Company has established and maintains disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that are effective in all material respects to ensure that material information relating to the Company, including any consolidated Subsidiaries, is made known to its
principal executive officer and principal financial officer by others within those entities. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period
covered by the most recently filed quarterly or annual periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed quarterly or annual


  
 17 








 
periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) or, to the Company’s knowledge, in
other factors that could significantly affect the Company’s internal control over financial reporting. 
 (ii) Accounting
Controls. Except as disclosed in the SEC Reports, the Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management’s general or
specific authorization, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

(jj) Placement Agent. The Company has taken no action that would give rise to any claim by any Person for brokerage commissions,
placement agent’s fees or similar payments relating to this Agreement or the transactions contemplated hereby. 
 3.2
Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the execution and delivery of this Agreement on the date first above written in this Agreement
to the Company as follows: 
 (a) Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its
obligations hereunder and thereunder. The execution, delivery and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law. 
 (b) No Intent to Take Over. Such Purchaser has no present actual intent to seek to effect, or to assist others
in effecting, a hostile acquisition of the Company. 
 (c) Experience of Such Purchaser. Such Purchaser understands that nothing in
the Agreement or any other materials presented to the Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Such Purchaser acknowledges that it must rely on legal, tax and investment
advisors of its own choosing in connection with its purchase of the Securities. 

  
 18 








 (d) Short Sales and Confidentiality Prior to the Date Hereof. Other than consummating the
transactions contemplated hereunder, such Purchaser has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, executed any purchases or sales, including Short Sales, of the
securities of the Company during the period commencing as of the time that such Purchaser first learned of the specific purchase and sale transaction being effected pursuant to this Agreement and ending immediately prior to the execution and
delivery hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no
direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement and to its counsel, such Purchaser has maintained the confidentiality of all disclosures made to it
in connection with the transaction expressly contemplated by this Agreement (including the existence and terms of this transaction). As of the date hereof, the Purchaser does not own any shares of the Company’s Common Stock that are borrowed.
Notwithstanding the foregoing, except as set forth in Section 3.2(e), for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the
availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions after the Second Closing Date. 

(e) Prohibition of Short Sales and Hedging Transactions. Each Purchaser agrees that beginning on the date of this Agreement and ending
on the Second Closing Date, Purchaser and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) Short Sale of the Company’s Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Company’s Common Stock. Without limiting the generality of the foregoing, neither the Purchaser nor any of its agents, representatives or affiliates will take, directly or
indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which would reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company.

 (f) No Government Review. Such Purchaser understands that no U.S. federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Securities purchased hereunder. 
 (g) Beneficial Ownership.
Immediately following such Purchaser’s purchase of Securities hereunder, such Purchaser, together with its Affiliates, will not beneficially own more than 9.99% of the Common Stock, including shares of Common Stock to be acquired upon exercise
of the Warrants. For purposes hereof, beneficial ownership and all determinations and calculations (including, without limitation, with respect to calculations of percentage ownership) shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. 

  
 19 








 ARTICLE IV 

OTHER AGREEMENTS OF THE PARTIES 

4.1 Integration. After this transaction, the Company shall not sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities such that the rules of the Trading Market would require shareholder approval of this
transaction prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. 

4.2 Securities Laws Disclosure; Publicity. The Company shall (a) issue a press release disclosing the material terms of the
transactions contemplated hereby simultaneously with the execution and delivery hereof (the “Press Release”), and (b) by 5:30 p.m. (New York City time) on the fourth Trading Day following the date hereof, file a Current Report
on Form 8-K disclosing the material terms of the transactions contemplated hereby and including the Transaction Documents as exhibits thereto. From and after the issuance of the Press Release, no Purchaser shall be in possession of any material,
non-public information received from the Company, any of its Subsidiaries or any of their respective officers, directors or employees that is not disclosed in the Press Release. The Company and each Purchaser shall consult with each other in issuing
any other press releases with respect to the transactions contemplated hereby, and, except as may be required by law, neither the Company nor any Purchaser shall issue any such press release or otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except
if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the
name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or any Trading Market, without the prior written consent of such Purchaser, except (i) in the Press Release, (ii) the
filing of this Agreement (including the signature pages hereto), the Prospectus Supplement, the Press Release, the Form 8-K and in its periodic reports with the Commission, and (iii) to the extent such disclosure is required by law or any
Trading Market, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this subclause (iii). The Company shall deliver a copy of the Solution 8-K to the Purchasers within one Trading Day following
the filing of such report. 
 4.3 Non-Public Information. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that the Company believes
constitutes material non-public information. Notwithstanding the foregoing, to the extent the Company delivers any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants and agrees that
such Purchaser shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public information. The Company understands and confirms that each Purchaser shall be relying on the foregoing
covenant in effecting transactions in securities of the Company. 

  
 20 








 4.4 Use of Proceeds. The Company will use the proceeds from the offering as
described in the Prospectus Supplement. 
 4.5 Indemnification of Purchasers. Subject to the provisions of this
Section 4.5, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling Persons (each, a “Purchaser
Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of
investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents or (b) any action instituted against a Purchaser, or any of them or their respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser or any governmental or regulatory agency, with respect to any
of the transactions contemplated by the Transaction Documents (unless such action is based upon a material breach of such Purchaser’s representations, warranties or covenants of the Transaction Documents or any agreements or understandings such
Purchaser may have with any such shareholder or any material violations by the Purchaser of state or federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any
action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense
thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to engage separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Purchaser Party except to the extent that (i) the engagement thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to
assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser
Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (i) for any settlement by a
Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed or (ii) to the extent, but only to the extent, that a loss, claim, damage or liability is attributable to any
Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. 

  
 21 








 4.6 Reservation and Listing of Securities. 

(a) The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents in
such amount as may then be required to fulfill its obligations in full under the Transaction Documents, but not less than the Required Minimum. 

(b) If, on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than the Required Minimum
on such date (such date, the “Authorized Share Failure”), then the Company shall promptly take all action necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to
reserve and have available the Required Minimum as of such date. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety
(90) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders or conduct a consent solicitation for the approval of an increase in the number of authorized shares of Common Stock to have
available the Required Minimum. 
 (c) The Company shall, if applicable: (i) in the time and manner required by the principal Trading
Market, prepare and file with such Trading Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on the date of such application, (ii) take all steps necessary to
cause such shares of Common Stock to be approved for listing or quotation on such Trading Market as soon as possible thereafter, (iii) provide to the Purchaser evidence of such listing or quotation and (iv) use commercially reasonable
efforts to maintain the listing of the Common Stock on a Trading Market, and the Company shall list all of the Securities on each of The NASDAQ Capital Market no later than the applicable Closing. The Company further agrees that if the Company
applies to have the Common Stock traded on any other Trading Market, it will include in such application all of the Securities and will take such other action as is necessary to cause all of the Securities to be listed on such other Trading Market
as promptly as possible. The Company will take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market, other than in connection with a Fundamental Transaction in which the Company is not the
surviving entity or in which all of the capital stock of the Company is acquired by an unaffiliated and unrelated Person, and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
such Trading Market. 
 4.7 Limitations on Subsequent Financings. The Company shall not consummate a Subsequent Financing (as
defined below) from the date hereof through the expiration of the Subscription Period without the prior written consent of the Purchasers holding a majority of the Securities issued and issuable pursuant to the Transaction Documents. 

4.8 Participation in Future Financings. 

(a) From the date hereof through the first anniversary of the Initial Closing Date, upon any proposed issuance by the Company or any of its
Subsidiaries of Common Stock, or Common Stock Equivalents for cash consideration, Indebtedness or a combination thereof, other than an Exempt Issuance (a “Subsequent Financing”), the Purchaser shall have the right to participate in
such Subsequent Financing up to its pro rata amount, calculated as its percentage equity ownership of the Company’s outstanding equity (assuming the conversion of all 

  
 22 








 
outstanding Preferred Stock into shares of Common Stock without regard to any blockers) (the “Participation Maximum”) on the same terms, conditions and price provided for in the
Subsequent Financing, unless the Subsequent Financing is an underwritten public offering, in which case the Company shall offer the Purchaser the right to participate in such public offering up to its pro rata amount when it is lawful for the
Company to do so. 
 (b) At least five Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to the
Purchaser a written notice of its intention to effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall inquire with the Purchaser whether it wishes to review the details of such proposed financing (such additional
notice, a “Subsequent Financing Notice”). Upon the request of the Purchaser, and only upon a request by the Purchaser, for a Subsequent Financing Notice, the Company shall promptly, but no later than one Trading Day after such
request, deliver a Subsequent Financing Notice to the Purchaser. The requesting Purchaser shall be deemed to have acknowledged that the Subsequent Financing Notice may contain material non-public information. The Subsequent Financing Notice shall
describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall
include a term sheet or similar document relating thereto as an attachment. 
 (c) If the Purchaser wishes to participate in such Subsequent
Financing it must provide written notice to the Company by not later than 5:30 p.m. (Pacific Time) on the fifth Trading Day after the Purchaser has received the Subsequent Financing Notice, that the Purchaser is willing to participate in the
Subsequent Financing and the amount of the Purchaser’s participation. If the Company receives no such notice from the Purchaser as of such fifth Trading Day, the Purchaser shall be deemed to have notified the Company that it does not elect to
participate and the Company may effect the Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice. 

(d) If by 5:30 p.m. (Pacific Time) on the fifth Trading Day after the Purchaser has received the Subsequent Financing Notice, the Company has
received written notification by the Purchaser of its willingness to participate in the Subsequent Financing (or to cause its designees to participate), then the Company shall effect the Subsequent Financing with the Purchaser (in the amount
indicated in its notification up to the Participation Maximum) and, with respect to the remaining portion of such Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice. 

(e) The Company must provide the Purchaser with a second Subsequent Financing Notice, and the Purchaser will again have the right of
participation set forth above in this Section 4.7, if the Subsequent Financing subject to the initial Subsequent Financing Notice is amended in any material respect or is not consummated for any reason on the terms set forth in such
Subsequent Financing Notice within 30 days after the date of the initial Subsequent Financing Notice. 
 (f) Notwithstanding anything to the
contrary in this Section 4.7 and unless otherwise agreed to by the Purchaser, the Company shall either confirm in writing to the Purchaser that the transaction with respect to the Subsequent Financing has been abandoned or


  
 23 








 
shall publicly disclose its intention to issue the securities in the Subsequent Financing, in either case in such a manner such that the Purchaser will not be in possession of any material,
non-public information, by the fifth Business Day following delivery of the Subsequent Financing Notice. If by such fifth Business Day, no public disclosure regarding a transaction with respect to the Subsequent Financing has been made, and no
notice regarding the abandonment of such transaction has been received by the Purchaser, such transaction shall be deemed to have been abandoned and the Purchaser shall not be deemed to be in possession of any material, non-public information with
respect to the Company or any of its Subsidiaries. 
 ARTICLE V 

MISCELLANEOUS 
 5.1
Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written
notice to the other parties, if the Closing has not been consummated on or before 5:00 p.m. (Pacific Time) on the tenth Trading Day after the date hereof through no fault of such Purchaser; provided, however, that no such termination
will affect the right of any party to sue for any breach by the other party (or parties). 
 5.2 Fees and Expenses. Except as
expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement; provided, however, that the Company shall pay the legal fees and expenses incurred by the Purchasers affiliated with Biotechnology Value Fund, L.P. in connection with
the transactions contemplated by this Agreement up to an aggregate amount of $50,000. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.

 5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such subject matter, which the parties acknowledge have been merged into such documents,
exhibits and schedules; provided that the foregoing shall not have any effect on any agreements that a Purchaser has entered into with the Company or any of its Subsidiaries prior to the date hereof with respect to any prior investment
made by such Purchaser in the Company. 
 5.4 Notices. Any and all notices or other communications or deliveries required
or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via email at the email address set forth on the
signature pages attached hereto or facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (Pacific Time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via email at the email address set forth on the signature pages attached hereto or facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (Pacific Time) on any Trading Day, (c) the second Trading Day following the date of mailing, if sent by U.S. nationally 

  
 24 








 
recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set
forth on the signature pages attached hereto. 
 5.5 Amendments; Waivers. No provision of this Agreement may be waived or
amended except in a written instrument signed, in the case of an amendment, by the Company and the Lead Investors or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default
with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. 
 5.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted
successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). The Purchasers may not assign this Agreement or any rights or
obligations hereunder without the prior written consent of the Company (other than by merger). 
 5.8 No Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
otherwise set forth in Section 4.5 of this Agreement. 
 5.9 Governing Law. All questions concerning the
construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law
thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its
respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of San Francisco. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City and County of San Francisco for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the
enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing 

  
 25 








 
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any
provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding. 
 5.10 Survival. The representations, warranties and covenants contained herein
shall survive the Closing and the delivery of the Securities for a period of one (1) year following the Closing. 
 5.11
Execution. This Agreement may be executed in two (2) or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party
and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature on this Agreement or any instrument pursuant to Section 5.5 hereof is delivered by facsimile
transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a legally valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof. 
 5.12 Severability. If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that
may be hereafter declared invalid, illegal, void or unenforceable. 
 5.13 Rescission and Withdrawal Right. Notwithstanding
anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or
in part without prejudice to its future actions and rights. 
 5.14 Replacement of Securities. If any certificate or
instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity or bond, if requested. The applicant for a new certificate
or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. 

  
 26 








 5.15 Remedies. In addition to being entitled to exercise all rights provided herein
or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance pursuant to the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any
loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be
adequate. 
 5.16 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any
Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction
Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any
proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents. 

5.17 Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any
amendments hereto. 
 (Signature Pages Follow) 

  
 27 








 IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

					
	ANTHERA PHARMACEUTICALS, INC.	 		 	Address for Notice:
		 		 	25801 Industrial Blvd, Suite B
		 		 	Hayward, California 94545
		 		 	Attn: Paul Truex
			
	 /s/ Paul Truex
	 		 	
	Name: Paul Truex	 		 	 With a copy to (which shall not constitute

notice):

	Title:   CEO	 		 
			
		 		 	Goodwin Procter LLP
		 		 	Three Embarcadero Center, 24th Floor
		 		 	San Francisco, California 94111
		 		 	Facsimile: (415) 520-9513
		 		 	Attn: Bradley A. Bugdanowitz, Esq.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; 

PURCHASER SIGNATURE PAGES FOLLOW] 

[Subscription Agreement]  

  
 28 








 IN WITNESS WHEREOF, the undersigned have caused this Subscription Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	 Biotechnology Value Fund, L.P.



 

			
	Signature of Authorized Signatory of Purchaser:	  	 /s/ Mark Lampert



 

			
	Name of Authorized Signatory:	 	 Mark Lampert

		
	Title of Authorized Signatory:	 	 President of BVF, Inc., itself GP of BVF Partners L.P., itself GP of Biotechnology Value Fund,
L.P.

		
	Email Address of Purchaser:	 	 loy@bvflp.com

		
	Fax Number of Purchaser:	 	 (415) 288-2394


  

			
	 Address for Notice of Purchaser:
  

One Sansome Street,
30th Floor
 San
Francisco, CA 94104



	  

	Telephone:	 	 (415) 525-8890

	Email:	 	 loy@bvflp.com

	Facsimile:	 	 (415) 288-2394

	Attention:	 	 Spike Loy

	  
 With a copy to (which shall not constitute
notice):
  
 Gibson, Dunn & Crutcher, LLP

555 Mission Street, Suite 3000
 San Francisco, CA 94105

Attn: Ryan A. Murr







 Address for delivery of securities for
Purchaser (if not same as address for notice): 
  

			
	 The Depository Trust Company

570 Washington Blvd – 5th Floor

Jersey City, NJ 07310



	Telephone:	 	 N/A

	Email:	 	 NA

	Facsimile:	 	 NA



			
	Attention:	 	   BNY Mellon/Branch Deposit Department for the account


 

			
	Subscription Amount:	 	 $6,949,000



 

			
	Shares of Series X Preferred Stock:	 	 6,949



 

			
	EIN Number:	 	  



  
 29 








 IN WITNESS WHEREOF, the undersigned have caused this Subscription Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	 Biotechnology Value Fund II, L.P.



			
		
	Signature of Authorized Signatory of Purchaser:	  	 /s/ Mark Lampert



			
		
	Name of Authorized Signatory:	 	 Mark Lampert

		
	Title of Authorized Signatory:	 	 President of BVF, Inc., itself GP of BVF Partners L.P., itself GP of Biotechnology Value Fund II,
L.P.

		
	Email Address of Purchaser:	 	 loy@bvflp.com

		
	Fax Number of Purchaser:	 	 (415) 288-2394


  

			
	Address for Notice of Purchaser:
	
	 One Sansome Street, 30th
Floor

	 San Francisco, CA 94104

	  



			
	Telephone:	 	 (415) 525-8890

	Email:	 	 loy@bvflp.com

	Facsimile:	 	 (415) 288-2394

	Attention:	 	 Spike Loy



			
	
	With a copy to (which shall not constitute notice):


			
	
	Gibson, Dunn & Crutcher, LLP
	555 Mission Street, Suite 3000
	San Francisco, CA 94105
	Attn: Ryan A. Murr


			
	
	Address for delivery of securities for Purchaser (if not same as address for notice):


			
	
	 The Depository Trust Company

	 570 Washington Blvd – 5th
Floor

	 Jersey City, NJ 07310



			
	Telephone:	 	 N/A

	Email:	 	 NA

	Facsimile:	 	 NA



			
	Attention:	 	   BNY Mellon/Branch Deposit Department for the account


			
		
	Subscription Amount:	 	 $4,542,00



			
		
	Shares of Series X Preferred Stock:	 	 4,542



			
		
	EIN Number:	 	  



  
 30 








 IN WITNESS WHEREOF, the undersigned have caused this Subscription Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	 	 Biotechnology Value Trading Fund OS,
L.P.



			
		
	Signature of Authorized Signatory of Purchaser:	 	 /s/ Mark Lampert



			
		
	Name of Authorized Signatory:	 	 Mark Lampert

	
	 Title of Authorized Signatory: President of BVF, Inc., itself GP of BVF
Partners L.P., itself Sole Member of BVF Partners OS, Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.

		
	Email Address of Purchaser:	 	 loy@bvflp.com

		
	Fax Number of Purchaser:	 	 (415) 288-2394



 

			
	 Address for Notice of Purchaser:
  

One Sansome Street,
30th Floor
 San
Francisco, CA 94104



	  

	Telephone:	 	 (415) 525-8890

	Email:	 	 loy@bvflp.com

	Facsimile:	 	 (415) 288-2394

	Attention:	 	 Spike Loy

	  

With a copy to (which shall not constitute notice):

 
 Gibson, Dunn & Crutcher, LLP

555 Mission Street, Suite 3000
 San Francisco, CA 94105

Attn: Ryan A. Murr







 Address for delivery of securities for
Purchaser (if not same as address for notice): 
  

			
	 The Depository Trust Company

570 Washington Blvd – 5th Floor

Jersey City, NJ 07310



	Telephone:	 	 N/A

	Email:	 	 NA

	Facsimile:	 	 NA



			
	Attention:	 	   BNY Mellon/Branch Deposit Department for the account


 

			
	Subscription Amount:	 	 $1,352,000



 

			
	Shares of Series X Preferred Stock:	 	 1,352



 

			
	EIN Number:	 	  



  
 31 








 IN WITNESS WHEREOF, the undersigned have caused this Subscription Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	 	 MSI BVF SPV, L.L.C.



			
		
	Signature of Authorized Signatory of Purchaser:	 	 /s/ Mark Lampert



			
		
	Name of Authorized Signatory:	 	 Mark Lampert



			
		
	Title of Authorized Signatory:	 	 President of BVF, Inc., itself GP of BVF Partners L.P., itself attorney-in-fact for MSI BVF SPV,
L.L.C.

		
	Email Address of Purchaser:	 	 loy@bvflp.com

		
	Fax Number of Purchaser:	 	 (415) 288-2394



 

			
	 Address for Notice of Purchaser:
  

One Sansome Street,
30th Floor
 San
Francisco, CA 94104



	  

	Telephone:	 	 (415) 525-8890

	Email:	 	 loy@bvflp.com

	Facsimile:	 	 (415) 288-2394

	Attention:	 	 Spike Loy

	  

With a copy to (which shall not constitute notice):

 
 Gibson, Dunn & Crutcher, LLP

555 Mission Street, Suite 3000
 San Francisco, CA 94105

Attn: Ryan A. Murr







 Address for delivery of securities for
Purchaser (if not same as address for notice): 
  

			
	 BNP Paribas Prime Brokerage

787 Seventh Avenue, 8th Floor

New York, NY 10019



	Telephone:	 	 212-471-6836

	Email:	 	 jose.nevarez@us.bnpparibas.com

	Facsimile:	 	 NA

	Attention:	 	Jose Nevarez

  

			
	Subscription Amount:	 	 $2,157,000



 

			
	Shares of Series X Preferred Stock:	 	 2,157



 

			
	EIN Number:	 	  



  
 32 








 EXHIBIT A 

Series X Preferred Stock Certificate of Designation 

  
 33 








 EXHIBIT B 

Series X-1 Preferred Stock Certificate of Designation 

  
 34 








 EXHIBIT C 

Form of Warrant 

  
 35 








 EXHIBIT D 

Subscription Notice 
  

	To:	                                    
 

  

	(1)	The undersigned Purchaser hereby elects to purchase                  shares of the Series X-1 Convertible Preferred Stock
(“Series X-1 Preferred Stock”) of Anthera Pharmaceuticals, Inc. (the “Company”), pursuant to the terms of the Subscription Agreement dated the 6th day of September, 2016 (the “Agreement”) between the Company and the
Purchasers named therein, and tenders herewith payment of the purchase price set forth below in full. 

  

	(2)	Please issue a certificate or certificates representing said shares of Series X-1 Preferred Stock in the name of the undersigned or in such other name as is specified below. 


 

			
	Number of shares of Series X Preferred Stock owned:	  	  

		
	Number of shares of Common Stock owned:	  	  



			
		
	Number of shares of Series X-1 Preferred Stock to be purchased:	  	  

		
	Price per share:	  	 $1,000

		
	Total purchase price:	  	  



			
		
	Address for delivery of physical certificates:	  	  

		
	or	  	


			
		
	For DWAC Delivery:	  	  

		
	DWAC Instructions:	  	  



			
		
	 Broker no:
	  	  



			
		
	Account no:	  	  


  

					
	PURCHASER
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

			
		 	Date:	 	  




  
 36